Glipizide is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation.
Glipizide
Glipizide; 29094-61-9; Glucotrol; Glydiazinamide; Glibenese
Bimode-SR, D-Glip, Diacon, Diaglip, Dibizide, G-Trol, Glez, Glibetic, Glide, Glip, Glipiriv, Glipy, Glucolip, Glucotrol, Glutop SR, Glylin-5, Glynase, Glytop-SR, Glyzip, Glyzip-CR, Godde, Lipi, Semi-Glynase, Tranase
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide
Oral absorption, 98-99% protein binding, hepatic metabolism and excreted through urine.
Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus depends on the functioning of beta cells in the pancreatic islets. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment.
2.5-5 mg/day as single dose initially per oral, dose may increase slowly.
Anti-diabetic drug
GI upsets, diarrhoea, nausea; allergic skin reactions, leucopenia, thrombocytopenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopenia.
Store it at room temperature.
445.535
C21H27N5O4S
29094-61-9
Hypoglycaemia, stress, elderly. Thyroid impairment; moderate hepatic or renal impairment. Monitor blood glucose concentration.
